JP2011510949A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510949A5
JP2011510949A5 JP2010544688A JP2010544688A JP2011510949A5 JP 2011510949 A5 JP2011510949 A5 JP 2011510949A5 JP 2010544688 A JP2010544688 A JP 2010544688A JP 2010544688 A JP2010544688 A JP 2010544688A JP 2011510949 A5 JP2011510949 A5 JP 2011510949A5
Authority
JP
Japan
Prior art keywords
metabolite
ulipristal acetate
patient
uterine
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010544688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510949A (ja
JP5906016B2 (ja
Filing date
Publication date
Priority claimed from US12/021,610 external-priority patent/US8299050B2/en
Application filed filed Critical
Publication of JP2011510949A publication Critical patent/JP2011510949A/ja
Publication of JP2011510949A5 publication Critical patent/JP2011510949A5/ja
Application granted granted Critical
Publication of JP5906016B2 publication Critical patent/JP5906016B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010544688A 2008-01-29 2009-01-28 子宮筋腫を治療するための酢酸ウリプリスタルの使用 Expired - Fee Related JP5906016B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/021,610 2008-01-29
US12/021,610 US8299050B2 (en) 2008-01-29 2008-01-29 Method for treating uterine fibroids
PCT/EP2009/050961 WO2009095418A1 (en) 2008-01-29 2009-01-28 Use of ulipristal for treating uterine fibroids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015004978A Division JP6138838B2 (ja) 2008-01-29 2015-01-14 子宮筋腫を治療するための酢酸ウリプリスタルの使用

Publications (3)

Publication Number Publication Date
JP2011510949A JP2011510949A (ja) 2011-04-07
JP2011510949A5 true JP2011510949A5 (https=) 2012-03-08
JP5906016B2 JP5906016B2 (ja) 2016-04-20

Family

ID=40551565

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010544688A Expired - Fee Related JP5906016B2 (ja) 2008-01-29 2009-01-28 子宮筋腫を治療するための酢酸ウリプリスタルの使用
JP2015004978A Expired - Fee Related JP6138838B2 (ja) 2008-01-29 2015-01-14 子宮筋腫を治療するための酢酸ウリプリスタルの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015004978A Expired - Fee Related JP6138838B2 (ja) 2008-01-29 2015-01-14 子宮筋腫を治療するための酢酸ウリプリスタルの使用

Country Status (20)

Country Link
US (5) US8299050B2 (https=)
EP (2) EP2252301B1 (https=)
JP (2) JP5906016B2 (https=)
KR (2) KR101571400B1 (https=)
AU (1) AU2009209652B2 (https=)
BR (1) BRPI0907028B8 (https=)
CA (2) CA2713254C (https=)
CY (1) CY1116485T1 (https=)
DK (1) DK2252301T3 (https=)
ES (1) ES2450592T3 (https=)
HR (1) HRP20140132T1 (https=)
IL (2) IL207182A (https=)
MX (1) MX2010008270A (https=)
NZ (1) NZ587439A (https=)
PL (1) PL2252301T3 (https=)
PT (1) PT2252301E (https=)
SI (1) SI2252301T1 (https=)
TW (1) TWI445537B (https=)
WO (1) WO2009095418A1 (https=)
ZA (1) ZA201006049B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
EP3865502A1 (en) * 2010-03-22 2021-08-18 Allergan Pharmaceuticals International Limited Compositions and methods for non-toxic delivery of cdb-2914
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
EP2641602A1 (en) * 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
WO2014050105A1 (en) * 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Amorphous ulipristal acetate
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
HK1213487A1 (zh) * 2012-12-14 2016-07-08 The Population Council, Inc. 銅子宮環
CN103006595B (zh) * 2012-12-25 2018-04-06 江苏亚邦爱普森药业有限公司 制备醋酸优力司特片的方法
JP6255038B2 (ja) * 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． 癌治療
HK1221169A1 (zh) * 2013-04-10 2017-05-26 Preglem S.A. 孕酮受体调节剂在子宫肌瘤疗法中的用途
US10444958B2 (en) * 2013-09-23 2019-10-15 Adobe Systems Incorporated Visual example-based user interface for adjusting photos along two dimensions
US10238722B2 (en) 2014-11-24 2019-03-26 Ramot At Tel-Aviv University Ltd. Pigment epithelium derived factor (PEDF) for the treatment of uterine fibroids
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
KR102086827B1 (ko) * 2017-12-14 2020-03-10 경희대학교 산학협력단 자궁근육종 치료용 울리프리스탈 아세테이트
KR102043349B1 (ko) * 2018-01-10 2019-11-12 경희대학교 산학협력단 대장암 치료 용도의 울리프리스탈 아세테이트
AU2021225117A1 (en) 2020-02-19 2022-10-06 Vélfag ehf. Device and method for filleting and pin-bone removal

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5468741A (en) * 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
UA37259C2 (uk) * 1995-02-02 2001-05-15 Шерінг Актієнгезеллшафт Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
WO1997041145A1 (en) 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
NZ504351A (en) * 1997-11-14 2002-10-25 Akzo Nobel Nv Contraceptive kit comprising progestogen and anti-progestogen and use in treating bleeding induced by a progestogen-only contraceptive regimen
US6262042B1 (en) * 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
ES2212912B1 (es) * 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
CA2516319C (en) 2003-02-28 2012-09-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method for preparing 17.alpha.-acetoxy-11.beta.-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
CA2573266C (en) 2004-07-09 2011-11-08 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
WO2007038796A1 (en) 2005-09-29 2007-04-05 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
EP2094275A2 (en) * 2006-12-28 2009-09-02 Repros Therapeutics Inc. Methods and formulations for improved bioavailability of antiprogestins
SI2148681T1 (sl) 2007-04-20 2016-07-29 Preglem S.A. Selektivni modulatorji progesterona v zdravljenju maternične krvavitve
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids

Similar Documents

Publication Publication Date Title
JP6138838B2 (ja) 子宮筋腫を治療するための酢酸ウリプリスタルの使用
JP2011510949A5 (https=)
KR20140050614A (ko) 자궁 섬유종과 관련된 과다 월경 출혈의 치료
TW201832767A (zh) 治療婦科疾病之組合物
US20190262361A1 (en) Progesterone Receptor Modulators for Use in the Therapy of Uterine Fibroids
US20230398127A1 (en) Use of combined oral contraceptives containing nomegestrol acetate and estradiol
Marimuthu et al. Efficacy of different doses of mifepristone in the management of uterine leiomyoma in a tertiary care centre
Genazzani et al. 2004 OUTLOOK ON HORMONE REPLACEMENT THERAPY
HK1194297A (en) Treatment of excessive menstrual bleeding associated with uterine fibroids